Can Healthcare Shares Really Shelter Portfolios From Geopolitical Storms?

Highlights

• Risk-off sentiment driven by Middle East tension and a fragile ceasefire has put defensive sectors, including healthcare, back in focus.

• Company-specific catalysts, from regulatory timelines to acquisitions, have complicated healthcare's traditional safe-haven behaviour this week.

• The UK healthcare category spans consumer health, medical devices, private hospitals and pharma, each with distinct defensive characteristics.

When geopolitics rattles markets, an old reflex kicks in: rotate towards companies whose earnings do not depend on the economic weather. This week has provided textbook conditions for that reflex. The FTSE 100 and FTSE 250 have been hovering near multi-week lows as investors weigh escalating Middle East tension, a ceasefire that feels anything but secure, and a US inflation reading that could reset interest-rate expectations. Gold, the classic refuge, has itself pulled back sharply after touching record highs earlier in the year, leaving equity investors searching for shelter within the stock market itself. Healthcare, alongside utilities and consumer staples, is where that search traditionally ends.

Yet the events of recent sessions have shown that the defensive label deserves scrutiny rather than blind faith. Heavyweight pharmaceutical shares have at times led London lower, dragged not by macroeconomics but by their own news flow. The question for investors is therefore more nuanced than it first appears: which parts of UK healthcare actually behave defensively, and under what conditions?

What makes a healthcare stock genuinely defensive?

The defensive case rests on demand. People do not postpone insulin, heart medication or cancer treatment because the economy slows or a conflict escalates, and health systems continue purchasing through downturns. Revenues in the sector are also geographically diversified, with the largest UK-listed names earning much of their income in overseas currencies — a feature that can cushion sterling-based investors when global stress weakens the pound.

But defensiveness has limits. Pharmaceutical shares carry their own idiosyncratic risks: clinical trials can fail, regulators can delay or decline approvals, and governments can squeeze drug prices. This week AstraZeneca (LSE:AZN) saw the US regulator extend its decision timeline on a key breast-cancer filing, while GSK (LSE:GSK) faced a sceptical initial reception to a major oncology acquisition. Neither development had anything to do with the macro backdrop, yet both moved the shares. A defensive sector, in other words, is not a sector without risk — it is a sector whose risks are largely uncorrelated with the economic cycle.

Which corners of UK healthcare offer the steadiest demand?

Arguably the purest defensive exposure in the category comes from consumer health. Haleon (LSE:HLN) sells toothpaste, pain relief and vitamins — small-ticket, habitual purchases that consumers maintain through almost any environment. Its revenues lack the explosive upside of a successful new medicine, but they also lack the binary risk of a regulatory verdict.

Medical technology occupies a middle ground. Smith & Nephew (LSE:SN.) depends on surgical procedures such as joint replacements and wound care, demand that is driven by demographics and hospital capacity rather than consumer confidence. ConvaTec (LSE:CTEC) supplies chronic-care products — ostomy, continence and wound therapies — where usage is ongoing and recurring by nature. Private hospital operator Spire Healthcare (LSE:SPI) benefits from long waiting lists in the public system, a driver more political than economic. Generics and injectables specialist Hikma Pharmaceuticals (LSE:HIK) sells medicines that health systems need regardless of conditions, with payers if anything more motivated to use cheaper generic options when budgets tighten.

Why are the pharma giants behaving differently right now?

The apparent paradox of this week — defensive stocks leading the index lower — dissolves on closer inspection. AstraZeneca and GSK are so large within the UK market that any company-specific repricing mechanically weighs on the benchmark. When stock-specific catalysts cluster, as they have done with a regulatory extension and a contested acquisition arriving in close succession, sector-level instincts are temporarily overwhelmed. This does not invalidate the defensive thesis; it simply demonstrates that the thesis operates over longer horizons than a single news cycle.

There is also a valuation dimension. Defensive sectors attract crowding during nervous periods, and crowded positions can unwind quickly when headlines improve. Investors who treat healthcare as a parking space rather than a long-term allocation often discover that the entrance is more comfortable than the exit.

Healthcare stocks listed in London are classified under the healthcare industry of the FTSE Industry Classification Benchmark, which splits the space into pharmaceuticals and biotechnology, and medical equipment and services. The category includes index heavyweights AstraZeneca (LSE:AZN) and GSK (LSE:GSK), consumer-health group Haleon (LSE:HLN), device makers Smith & Nephew (LSE:SN.) and ConvaTec (LSE:CTEC), and service providers such as Spire Healthcare (LSE:SPI), alongside numerous earlier-stage life-sciences companies quoted on AIM. Many of these names sit within the FTSE 350, and the pharmaceutical majors are among the largest constituents of the UK's flagship index, giving the sector outsized influence on overall market direction.

How does the macro backdrop feed into the sector from here?

Several macro threads will shape healthcare's behaviour in the sessions ahead. The US inflation reading in focus this week feeds directly into interest-rate expectations, and rate-sensitive valuations matter for a sector whose worth lies in long-dated future cash flows. Currency movements driven by geopolitical stress alter the sterling value of overseas earnings. And the policy environment for medicine pricing in the United States remains the sector's most persistent overhang, capable of resurfacing whenever political attention swings back to healthcare costs.

For now, the picture is one of a sector doing roughly what it is supposed to do — offering earnings streams insulated from the economic cycle — while reminding investors that insulation from the cycle is not insulation from events. In a market hovering near multi-week lows, that distinction is worth keeping in mind. The defensive playbook still works; it just requires reading past the first page.